Lifecore Biomedical, Inc. DE disclosed a material event
SEC 8-KRead source ↗
Lifecore Biomedical, Inc. DE is a US-listed company in the life sciences tools & services industry. Its financial year ends in May.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$10
Forward price-to-sales vs peers
Base case. Range ~$8.4–$24. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Lifecore Biomedical, Inc. DE valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds50 adding, 41 cuttingOf 13 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 15% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Lifecore Biomedical, Inc. DE's latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 0.5 against the S&P 500.
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$0.19 against an average estimate of -$0.22: beat by 14.6%
- Share reaction
- +11.3% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
- Next report
- November 3, 2026
Price chart
- 1 day-0.2%
- 1 week-0.8%
- 1 month-2.3%
- This year-21.9%
- 1 year-11.1%
- 5 years-33.2%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 5, 2026
- Next results (est.)
- November 5, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Agreement
Lifecore Biomedical, Inc. DE entered a material agreement
SEC 8-KRead source ↗ - Agreement
Lifecore Biomedical, Inc. DE entered a material agreement; made a public disclosure
SEC 8-KRead source ↗ - Results
Lifecore Biomedical, Inc. DE reported results; made a public disclosure
SEC 8-KRead source ↗
Valuation models
We value Lifecore Biomedical, Inc. DE as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: no revenue, margin or share count to start from |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$10 ~$8.4–$24 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$10 ~$8.4–$24 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lifecore Biomedical, Inc. DE with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 3, 2026, after the close. Analysts expect revenue of $26m for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.01 | −87% | $122m | +61% |
| Next | −$0.88 | +13% | $131m | +8% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −3.6% on 90 days ago. In the last 30 days, 0 analysts raised Lifecore Biomedical, Inc. DE's forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.04 | −$0.98 |
| 60 days ago | −$1.01 | −$0.88 |
| 30 days ago | −$1.01 | −$0.88 |
| 7 days ago | −$1.01 | −$0.89 |
| Now | −$1.01 | −$0.88 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.22 | −$0.19 | +14.6% |
| Mar 2026 | −$0.29 | −$0.43 | −48.3% |
| Dec 2025 | −$0.16 | −$0.16 | 0.0% |
| Feb 2025 | −$0.15 | −$0.47 | −213.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 5.8% of tradable shares
- Days to cover
- 2.92 at average volume
- Short interest, 1 month
- −32% to October 15, 2026
- Held by institutions
- 73% of shares
- Held by insiders
- 3.0% of shares
- Employees
- 382 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| LFCR | +2% | −42% | −5% | +20% | +10% | −22% |
| Industry peers (median) | +5% | −53% | −3% | −15% | −7% | +16% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| LFCR | 42% | 50% | 42% | 67% | 50% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| LFCR | −38% | −46% | −77% | −55% | −33% | −59% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 89% from June 25, 2018 to March 17, 2023. Getting back needed a 825% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $3.66 – $8.82
- From 52-week high
- −27.6%
- vs 50-day average
- +17.1%
- vs 200-day average
- +16.1%
- Volatility (1 year)
- 81%
- Beta vs S&P 500
- 0.51
Share price after results
- Next day
- 5 up, 7 down typical move ±13.8%
- After a week
- 3 up, 9 down typical move ±17.1%
- After a month
- 4 up, 8 down typical move ±13.5%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 5, 2026 | +11.3% | −0.4% | +9.7% | 0.0% |
| May 6, 2026 | −7.6% | +1.1% | −12.8% | +9.1% |
| March 16, 2026 | −33.3% | +1.3% | −38.1% | −17.7% |
| November 6, 2025 | +1.2% | −1.0% | +16.5% | +10.9% |
| August 7, 2025 | −6.3% | +0.7% | −4.0% | −5.7% |
| April 3, 2025 | −26.5% | −10.5% | −20.6% | −2.5% |
| January 2, 2025 | +2.6% | +1.0% | −15.3% | −20.1% |
| October 4, 2024 | +8.1% | 0.0% | −1.9% | +27.2% |
| August 26, 2024 | −21.0% | −0.1% | −27.2% | −21.0% |
| April 1, 2024 | +4.0% | −0.8% | +13.2% | +20.9% |
| March 20, 2024 | −29.9% | +1.3% | −28.1% | −7.0% |
| August 31, 2023 | −13.2% | 0.0% | −17.4% | −19.5% |
Fundamentals
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Contract Development and Manufacturing Organization | $90.1M | 69.9% | ▼ 6.7% |
| HA Manufacturing | $38.8M | 30.1% | ▲ 22.5% |
From Lifecore Biomedical, Inc. DE's 10-K filed August 7, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Who owns it
Funds buying and selling- Reported value
- $133M
- Institutions reporting
- 99
- Shares held vs prior quarter
- ▲ 1.2%
- Positions opened / closed
- 15 / 19
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Wynnefield Capital Inc | $24.7M | 4.7M | 18.5% | 0.0% |
| Legion Partners Asset Management, LLC | $23.4M | 4.5M | 17.6% | 0.0% |
| Greenhaven Road Investment Management, L.P. | $16.8M | 3.2M | 12.6% | ▼ 9.8% |
| 325 Capital LLC | $15.2M | 2.9M | 11.4% | ▲ 33.9% |
| Blackrock, Inc. | $10.6M | 2.0M | 7.9% | ▲ 7.2% |
| Vanguard Capital Management LLC | $6.8M | 1.3M | 5.1% | ▼ 0.1% |
| Geode Capital Management, LLC | $4.5M | 856K | 3.4% | ▲ 5.0% |
| Morgan Stanley | $4M | 769K | 3.0% | ▲ 0.6% |
| State Street Corp | $3.5M | 668K | 2.6% | ▲ 4.1% |
| Quinn Opportunity Partners LLC | $2.4M | 453K | 1.8% | 0.0% |
| Dcf Advisers, LLC | $2.2M | 425K | 1.7% | 0.0% |
| Wittenberg Investment Management, Inc. | $1.6M | 314K | 1.2% | ▲ 4.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lifecore Biomedical, Inc. DE's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
- August 5, 2026
- May 6, 2026
- March 16, 2026
- November 6, 2025
- August 7, 2025
- April 3, 2025
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Lifecore Biomedical, Inc. DE in brief
- What does Lifecore Biomedical, Inc. DE do?
- Lifecore Biomedical, Inc. DE is a US-listed company in the life sciences tools & services industry. Its financial year ends in May.
- What is Lifecore Biomedical, Inc. DE's stock ticker?
- Lifecore Biomedical, Inc. DE trades under the ticker LFCR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Lifecore Biomedical, Inc. DE's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Wynnefield Capital Inc, Legion Partners Asset Management, LLC and Greenhaven Road Investment Management, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- When is Lifecore Biomedical, Inc. DE's next earnings date?
- Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lifecore Biomedical, Inc. DE announces its own schedule.
Follow research on Lifecore Biomedical, Inc. DE
New research on the companies we cover arrives in the weekly email. Free, one email a week.